Man Group plc Takes Position in TransMedics Group, Inc. $TMDX

Man Group plc acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 11,327 shares of the company’s stock, valued at approximately $752,000.

Several other large investors have also recently bought and sold shares of TMDX. Royal Bank of Canada boosted its position in shares of TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares during the period. Finally, M&T Bank Corp acquired a new stake in shares of TransMedics Group in the second quarter valued at about $209,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TMDX has been the topic of several recent analyst reports. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Needham & Company LLC decreased their price target on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Trading Up 3.2%

Shares of TransMedics Group stock opened at $86.98 on Friday. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The business has a 50 day moving average price of $79.71 and a 200 day moving average price of $92.23. The company has a market capitalization of $3.01 billion, a P/E ratio of 22.36 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.92 EPS. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.